[go: up one dir, main page]

MX2011011177A - Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina. - Google Patents

Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina.

Info

Publication number
MX2011011177A
MX2011011177A MX2011011177A MX2011011177A MX2011011177A MX 2011011177 A MX2011011177 A MX 2011011177A MX 2011011177 A MX2011011177 A MX 2011011177A MX 2011011177 A MX2011011177 A MX 2011011177A MX 2011011177 A MX2011011177 A MX 2011011177A
Authority
MX
Mexico
Prior art keywords
methylcarbamoylmethyl
quinazoline
piperidin
chloro
preparation
Prior art date
Application number
MX2011011177A
Other languages
English (en)
Inventor
David Dermot Patrick Laffan
Kay Alison Boardman
Oliver Robert Cunningham
William Goundry
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2011011177A publication Critical patent/MX2011011177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se describen procesos para preparar 4-(3-cloro-2- fluoroanilino)7-metoxL6-{[1-(N-metilcarbamoilmetil)piperidin-4- il]oxi}quinazolina, sus sales de lo mismo y los intermedios utilizados en el proceso.
MX2011011177A 2009-04-23 2010-04-22 Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina. MX2011011177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17199409P 2009-04-23 2009-04-23
PCT/GB2010/050653 WO2010122340A2 (en) 2009-04-23 2010-04-22 Process 738

Publications (1)

Publication Number Publication Date
MX2011011177A true MX2011011177A (es) 2011-11-18

Family

ID=42224659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011177A MX2011011177A (es) 2009-04-23 2010-04-22 Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina.

Country Status (14)

Country Link
US (1) US8450482B2 (es)
EP (1) EP2421827A2 (es)
JP (1) JP2012524769A (es)
KR (1) KR20120007059A (es)
CN (1) CN102459174A (es)
AR (1) AR076407A1 (es)
AU (1) AU2010240717A1 (es)
BR (1) BRPI1013854A2 (es)
CA (1) CA2758610A1 (es)
IL (1) IL215388A0 (es)
MX (1) MX2011011177A (es)
SG (1) SG174893A1 (es)
TW (1) TW201041871A (es)
WO (1) WO2010122340A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
CN108503596A (zh) * 2018-03-14 2018-09-07 盐城师范学院 一种新的厄洛替尼及其中间体的制备方法
CN108440420A (zh) * 2018-03-22 2018-08-24 盐城师范学院 酪氨酸激酶抑制剂拉帕替尼及其关键中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200813014A (en) 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
MXPA06003113A (es) * 2003-09-19 2006-06-20 Astrazeneca Ab Derivados de quinazolina.
WO2005115145A2 (en) * 2004-05-20 2005-12-08 Wyeth Quinone substituted quinazoline and quinoline kinase inhibitors
WO2009138779A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline
EP2303276B1 (en) 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline

Also Published As

Publication number Publication date
WO2010122340A3 (en) 2011-09-09
CN102459174A (zh) 2012-05-16
JP2012524769A (ja) 2012-10-18
TW201041871A (en) 2010-12-01
AR076407A1 (es) 2011-06-08
WO2010122340A8 (en) 2011-12-15
IL215388A0 (en) 2011-12-29
EP2421827A2 (en) 2012-02-29
KR20120007059A (ko) 2012-01-19
US8450482B2 (en) 2013-05-28
US20120108814A1 (en) 2012-05-03
CA2758610A1 (en) 2010-10-28
AU2010240717A1 (en) 2011-10-27
SG174893A1 (en) 2011-11-28
BRPI1013854A2 (pt) 2017-05-16
WO2010122340A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
MY159522A (en) Administration of dipeptidyl peptidase inhibitors
IL236922A0 (en) Salts and solid forms of (4))-4)-3-(s-morpholinomethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-6,2-dione and compounds containing them and methods of their use
WO2012077136A3 (en) Process for the preparation of benzimidazole derivatives and its salts
ATE535282T1 (de) Benzoazepin-oxy-essigsäurederivate als ppar-delta-agonisten zur erhöhung von hdl-c, senkung von ldl-c sowie cholesterinsenkung
AU2011278832A8 (en) Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
MY161966A (en) Methods and genotyping panels for detecting alleles, genomes, and transcriptomes
IL180859A0 (en) Imatinib mesylate alpha form and production process therefor
EP2305995A4 (en) Process for producing common rail, and common rail
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
TN2010000299A1 (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydropy-ran-4-yl)-propionamide
ZA201103727B (en) Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine
MA33290B1 (fr) Pipéridines substituées
MY183041A (en) Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- {[1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
MX2011011177A (es) Proceso para la preparacion de 4-(3-cloro-2-fluoro-anilino)-7-meto xi-6-[1-(n-metilcarbamoilmetil) piperidin-4-il] quinazolina.
TW200745036A (en) Chemical process
MA33291B1 (fr) Pipéridines substituées
ZA201004467B (en) Triazolopyridazines as pari inhibitors,production thereof,and use as medicaments
WO2010112589A3 (de) Schnittschablone aus keramik
ZA200807281B (en) CCR5 antagonists useful for treating HIV
HK1164285A (en) Process for the preparation of 4-(3-chloro-2-fluoro-anilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)-piperidin- 4-yl]oxy}quinazoline
UA103998C2 (ru) Дифумарат 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
WO2010061208A3 (en) Combination comprising a quinazoline derivative and a taxane
EP2351928A4 (en) Common rail, common rail holder, and method for producing common rail
IL217351A0 (en) 2-amino-2-phenyl-alkanol derivatives, prepartion thereof, and pharmaceutical compositons containing same

Legal Events

Date Code Title Description
FA Abandonment or withdrawal